Predictions for the Generic Drug Sector in 2018
PCI Synthesis shares expected trends in the industry within the next year
Posted: January 9, 2018
Contract Pharma published PCI Synthesis’s Predictions for the Generic Drug Sector in 2018. Here are some of the trends that PCI Synthesis shared, which they expect will impact the industry next year
Read the Full Article and watch the video »
Related posts:
Think CROs in China and India are cheaper? Here’s the real story.
What’s Driving the CMO Market? – The Opportunities and Challenges Ahead
Six Tips for Leveraging Values, Ethics and Compliance in Successful Drug Development
Time to address price hikes in US generic drugs
Outsourcing Your API Manufacturing to Asia?
About the Author
Ed is President & CEO of SEQENS North America (formerly PCI Synthesis). He serves as a co-chair of the New England CRO/CMO Council and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a long standing member of the American Chemical Society and advises the Bulk Pharmaceutical Task Force of the Society of Chemical Manufacturer’s and Affiliates (SOCMA)...